Octreotide

Octreotide is a synthetic octapeptide analog of the naturally occurring hormone somatostatin, developed by Sandoz (now Novartis). While native somatostatin has a half-life of only 2-3 minutes, making it impractical for clinical use, octreotide's structural modifications extend its half-life to approximately 90-120 minutes, allowing for practical subcutaneous administration. A long-acting repeatable (LAR) depot formulation further extends the dosing interval to once every 4 weeks.

Somatostatin and its analogs exert broad inhibitory effects through five somatostatin receptor subtypes (SSTR1-5). Octreotide has highest affinity for SSTR2 and SSTR5, which are the predominant subtypes expressed on many neuroendocrine tumors and in the pituitary gland. Through these receptors, octreotide suppresses the secretion of growth hormone (GH), insulin, glucagon, vasoactive intestinal peptide (VIP), serotonin, and numerous other hormones and peptides.

The primary clinical applications of octreotide are in the management of acromegaly (GH excess) and in the control of symptoms associated with functioning neuroendocrine tumors, including carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). In acromegaly, octreotide reduces GH and IGF-1 levels and can shrink pituitary adenomas in a subset of patients. In neuroendocrine tumors, it provides symptomatic relief from diarrhea, flushing, and other hormone-mediated symptoms, and the PROMID and CLARINET trials demonstrated antiproliferative effects that slow tumor growth.

Octreotide is also used in acute management of variceal bleeding, where it reduces splanchnic blood flow, and in the management of postoperative pancreatic fistulas. Its broad inhibitory effects on gastrointestinal secretion and motility have led to numerous additional off-label applications in gastroenterology and endocrinology.